A
Altimmune, Inc. (ALT)
NGM – Real vaqt narxi. Valyuta: USD
3.15
+0.15 (5.17%)
Bozor ochiq: Aug 12, 2026, 11:52 AM EDT
3.04
+0.04 (1.18%)
Oldingi bozordan keyin: Aug 11, 2026, 7:57 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
3.15
+0.15 (5.17%)
Bozor ochiq: Aug 12, 2026, 11:52 AM EDT
3.04
+0.04 (1.18%)
Oldingi bozordan keyin: Aug 11, 2026, 7:57 PM EDT
Altimmune, Inc., kechki klinik bosqichdagi biofarmatsevtika kompaniyasi, jiddiy jigar kasalliklari uchun yangi davolash usullarini ishlab chiqishga qaratilgan. Uning asosiy mahsulot nomzodi pemvidutide bo'lib, u GLP-1/glyukagon ikkilamchi retseptor agonisti bo'lib, u metabolik disfunksiya bilan bog'liq steatohepatit, alkogol iste'moli buzilishi va alkogol bilan bog'liq jigar kasalliklarini davolash uchun 3-bosqichli klinik sinovdan o'tmoqda. Kompaniya 1997 yilda tashkil etilgan va shtab-kvartirasi Gaithersburg, Merilendda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Mr. Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer |
| Mr. Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Mr. Jerome Benedict Durso | Chairman, CEO & President |
| Mr. Raymond M. Jordt M.B.A., M.S. | Chief Business Officer |
| Mr. Tony Blandin B.S. | Vice President of Quality & Compliance Management |
| Ms. Linda M. Richardson | Chief Commercial Officer |
| Ms. Robin E. Abrams J.D. | Chief Legal Officer & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-07-28 | 8-K | alt-20260728x8k.htm |
| 2026-06-16 | 8-K | tm2618087d1_8k.htm |
| 2026-05-13 | S-8 | alt-20260513xs8.htm |
| 2026-05-13 | 8-K | alt-20260513x8k.htm |
| 2026-05-13 | 10-Q | alt-20260331x10q.htm |
| 2026-04-24 | 8-K | tm2612493d2_8k.htm |
| 2026-04-22 | S-3MEF | tm2612458d1_s3mef.htm |
| 2026-04-16 | 8-K | alt-20260416x8k.htm |
| 2026-03-17 | DEF 14A | alt-20260416xdef14a.htm |
| 2026-03-17 | ARS | tm262295d2_ars.pdf |